



Adherence to the mediterranean diet and physical activity in relation to sarcopenia: a cross-sectional epidemiological cohort study

Alejandro Álvarez-Bustos^{1,2} · Helio José Coelho-Junior^{1,3,4} · Jose Antonio Carnicero^{1,2,5} · Francisco José García-García^{1,6} · Emanuele Marzetti^{3,4} · Leocadio Rodríguez-Mañas^{1,2,7,8}

Received: 2 February 2025 / Accepted: 28 April 2025
© The Author(s) 2025

Abstract

Background Adoption of healthy lifestyle habits has been proposed as successful strategies to counteract sarcopenia.

Aims To explore the association of physical activity (PA) and adherence to the mediterranean diet (MD), individually and synergically, with sarcopenia.

Methods The present cross-sectional study examined data of the Toledo Study of Healthy Ageing. Data of community-dwelling adults aged 65+ years were analyzed. Sarcopenia was defined according to the Foundation for the National Institutes of Health, standardized to our population (sFNIH) and the European Working Group on Sarcopenia (EWGSOP2). PA levels (Physical Activity Scale for the Elderly, PASE) and adherence to the MD (MEDiterranean Diet Adherence Screener-MEDAS) were estimated using self-reported instruments. Binary regression models were conducted to test associations.

Results Data of 1457 individuals (mean age 74.68 ± 5.77 years; 54.91% women) were analyzed. Among them, 331 (22.72%, sFNIH) and 202 (13.86%, EWGSOP2) met sarcopenia criteria. PA levels (ORs: 0.91–0.95, $p < 0.05$) and adherence to the MD (ORs: 0.82–0.86, $p < 0.05$) were significantly and negatively associated with the prevalence of sarcopenia, regardless of the definition used. Nevertheless, no significant interactions were observed among healthy lifestyle habits. According to sarcopenia-related domains, PA levels and adherence to the MD were negatively associated with dynapenia, meanwhile, PA levels were associated with low lean mass (sFNIH) and adherence to the MD was inversely associated with poor mobility.

Conclusions PA and adherence to the MD are independently associated with sarcopenia. Moreover, specific associations were observed between sarcopenia domains. Nevertheless, no significant interaction was observed between them.

Keywords Sarcopenia · Physical activity · Mediterranean diet · Low handgrip strength · Low gait speed · Low muscle mass

✉ Leocadio Rodríguez-Mañas
leocadio.rodriguez@salud.madrid.org

¹ Biomedical Research Center Network for Frailty and Healthy Ageing (CIBERFES), Institute of Health Carlos III, Madrid, Spain

² Instituto de Investigación Biomédica La Paz (IdiPaz), Madrid, Spain

³ Department of Geriatrics and Orthopedics, Università Cattolica del Sacro Cuore, Rome, Italy

⁴ Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy

⁵ Fundación para la Investigación Biomédica del Hospital Universitario de Getafe, Getafe, Spain

⁶ Department of Geriatrics, Hospital Virgen del Valle, Toledo, España

⁷ Department of Geriatrics, Hospital Universitario de Getafe, Carretera de Toledo, Km 15.5, 28029, Getafe, Madrid, Spain

⁸ Servicio de Geriatría, Hospital Universitario de Getafe, Carretera de Toledo, Km 12.5, Getafe, Madrid 28905, Spain

Background

Preserving functional independence is a priority for successful aging [1, 2]. Sarcopenia is a disease [3] characterized by the presence of dynapenia, low muscle mass, and mobility impairment [4]. The prevalence of sarcopenia increases with age, reaching more than 20% of individuals aged 65+ years [5]. The progression of sarcopenia deserves concern, given its close association with the occurrence of multiple negative health events [6], such as falls [7], frailty [8, 9], disability [10, 11], and death [12].

The management of sarcopenia is a topic under intense debate. Currently, despite the efforts to explore possible biomarkers of sarcopenia [13, 14], there is no available pharmacological treatment that might effectively reduce its prevalence. On the other hand, the adoption of healthy lifestyle habits is widely mentioned by panels of experts, as a successful approach that might contribute to improvements in sarcopenic status [15, 16]. Among the myriads of healthy lifestyle habits, substantial attention has been given to physical activity (PA). For instance, a recent pooled analysis by Sánchez-Sánchez et al. [17] found that high PA levels were significantly associated with a lower prevalence of sarcopenia. Nevertheless, only three of the studies included examined sarcopenia according to the most recent guidelines [17]. Moreover, the extension by which PA is associated with specific sarcopenia-related domains still needs to be further explored [17]. These data are important to understand what type of complementary strategy would be necessary to effectively manage sarcopenia.

Compliance with healthy dietary patterns is another healthy lifestyle habit with cumulative synergistic effects on health in the development of different diseases [18–20]. Specifically, investigations have observed that a high adherence to the Mediterranean Diet (MD), characterized by a high consumption of olive oil, vegetables, fruit, moderate consumption of fish and poultry, and low consumption of red meat and sweets, as well as moderate consumption of wine at meals [19–21], is associated with specific domains of sarcopenia, such as muscle strength [22–24] and gait speed [24]. However, available evidence includes investigations conducting in non-Mediterranean populations and the assessment of the adherence to the MD using non-validated instruments. Furthermore, existing studies have provided conflicting results [25–28].

Notably, individuals with high PA levels might be more engaged in adhering to healthy nutritional habits [29]. Furthermore, it has been proposed that the significant associations observed between MD and health parameters might be a product of a mediterranean way of living, which includes, among other, regular practice of PA, instead of solely nutritional patterns. Taken together, this scenario suggests that a

possible interaction between PA and adherence to the MD might exist.

Therefore, to expand the current knowledge, the present study aims to explore the individual and synergic (interactions) between PA and/or adherence to the MD with sarcopenia status and domains.

Methods

The present study examined data from the second wave of assessments (conducted between 2011 and 2013) of the Toledo Study of Healthy Ageing (TSHA) database [30]. The TSHA is a longitudinal population-based study that examined community-dwelling older adults aged 65+ years who lived in the province of Toledo, Spain. The TSHA was conducted according to ethical standards laid down in the Declaration of Helsinki and was approved by the Clinical Research Ethics Committee of the Toledo Hospital, Spain (ID:15072010.93). All participants agreed to be part of the study and voluntarily signed the informed consent prior to enrolment. In the present study, all participants with no missing data for the variables examined were included.

Sarcopenia

Sarcopenia was operationalized according to definitions created by experts' panels, including (a) the Foundation for the National Institutes of Health (FNIH) [31, 32], standardized to our population (FNIHs) [33]; and (b) the European Working Group on Sarcopenia in Older People (EWG-SOP2) [4]. Participants were defined as sarcopenic if they had a combination of (i) dynapenia, operationalized according to isometric handgrip strength (IHG), (ii) low muscle mass, based on appendicular lean soft mass (aLM), and (iii) mobility impairments, estimated according to gait speed. This classification refers to the categories established by the FNIH guidelines and to severe sarcopenia, according to the EWG-SOP2.

IHG was evaluated using a hydraulic Jamar (J. A. Preston Corporation, Clifton, NJ, USA) dynamometer. Participants were assessed according to standard procedures [34]. The highest performance (in kilogram) of three trials was recorded and used for analysis. One minute of resting was provided between attempts. aLM was assessed through a whole-body dual-energy X-ray absorptiometry (DXA) on a Hologic (Bedford, MA, USA) scanner. Body Mass Index (BMI) was obtained according to standard procedures (adjusted to the nearest 0.1) and then BMI-adjusted by ALM (aLM/BMI) was determined. For the gait speed test, participants were instructed to walk meters at their usual pace. The fastest of two trials (m/s) was analyzed.

Mediterranean diet

The Mediterranean Diet Adherence Screener (MEDAS) questionnaire [35] was used to estimate adherence to the MD. The MEDAS is a self-reported questionnaire in which individuals are asked 14 questions about the frequency and quantity of consumption of certain foods (i.e., olive oil, fruits and vegetables, legumes, fish and seafood, white, red and processed meats, butter, carbonated beverages, wine, nuts, sweets) and methods of cooking (sofrito). Each item is assigned a score of 0 or 1, resulting in a total possible score ranging from 0 to 14, with higher results indicating highest levels of adherence to the MD.

Physical activity

PA levels were assessed through the Physical Activity Scale for the Elderly (PASE) [36]. This tool possesses 10 questions that assess the duration, intensity and frequency of leisure, domestic and work activities performed by older adults in the last week. The final score is obtained by multiplying whether the individual participated in the activity, or the amount of time spent in the activity by the empirically derived item weights, which are summed. Due to the overall score ranges from 0 to 400 or more [36], we standardized the score by dividing it by 10.5, equivalent to increasing the time spent walking outside the home by 30 min per day.

Covariates

The presence of comorbidities (evaluated through the Charlson Comorbidity Index [37]), number of drugs intake, formal education (non-educated, non-finished primary education, and finished primary education/superior), the capacity to perform the basic (Katz Index [38]) and instrumental activities of daily living (Lawton and Brody Index [39]) and smoking status were considered as covariates.

Statistical analysis

Descriptive data was presented as mean (standard deviation) and N (percentages), respectively. Differences between groups according to the presence of sarcopenia were tested using Mann-Whitney for continuous variables and Chi-squared tests for the comparison between categorical variables.

Different models were conducted to test the associations between PA and/or adherence to the MD and sarcopenia. The association between these two variables were tested individually by performing logistic regression models adjusted for different covariates such as age, sex, comorbidity, number of drugs intake, educational level, Katz Index score,

Lawton Index score and smoking status. Subsequently, we performed the same approach, but including both the PASE (divided by 10.5) and MEDAS scores from the first model. Next, we included the interaction variable of both independent variables in the model.

Statistical significance was set at p -value < 0.05. All the analyses were computed using R for windows version 4.1.2.

Results

The main characteristics of study participants according to sarcopenia status is shown in Table 1. Data of one thousand four hundred fifty-seven (mean age 74.68 ± 5.77 years; 54.91% women) older adults were examined. Among them, 331 (22.72%) and 202 (13.86%) were identified as sarcopenic according to sFNIH and EWGSOP2 definitions, respectively. Comparisons between participants with and without sarcopenia indicated that those sarcopenic were mostly women, were significantly older, had a higher prevalence of comorbidities, and lower PASE and MEDAS scores, suggesting low levels of PA and adherence to the MD.

Individual associations between MD, PA, and sarcopenia

Table 2 shows the association between PA levels and the adherence to the MD with sarcopenia. Adherence to MD [sFNIH OR (95%CI): 0.84 (0.77, 0.92), p -value < 0.001; EWGSOP2 OR (95%CI): 0.82 (0.74, 0.91), p -value < 0.001] and PA levels [sFNIH OR (95%CI): 0.94 (0.90, 0.97), p -value 0.002; EWGSOP2 OR (95%CI): 0.95 (0.90, 0.99), p -value 0.018] were negatively and significantly associated with the presence of sarcopenia, regardless of the covariates included in the model. The inclusion of adherence to MD or PA levels as adjustment variables in the models assessing its respective roles did not change the results (Table 3).

When the analysis was conducted according to specific sarcopenia domains, PA was significantly and inversely associated with dynapenia, regardless of the cut-off point used (Supplementary Table 1). It was also significantly and negatively associated with low muscle mass, when it was operationalized according to the sFNIH definition [OR (95%CI): 0.96 (0.93, 0.99), p -value 0.011], but not with the EWGSOP2 ($p > 0.05$ for all models). On the other hand, adherence to the MD was significantly and inversely associated with dynapenia and mobility impairments, but not with low muscle mass, regardless of the definition used to assess sarcopenia (Supplementary Table 2). Similar results were observed when PA and the adherence to the MD were included as covariates (Supplementary Table 3).

Table 1 Demographic characteristics of the participants according to the presence of sarcopenia

	Whole sample	sFNIH			EWGSOP2		
		No sarcopenia	Sarcopenia	p-value	No sarcopenia	Sarcopenia	p-value
N	1457	1126 (77.28%)	331 (22.72%)		1255 (86.14%)	202 (13.86%)	
Women, n (%)	800 (54.91%)	526 (46.71%)	274 (82.78%)	<0.001	695 (55.38%)	105 (51.98%)	<0.001
Age, mean (SD)	74.68 (5.77)	73.81 (5.50)	77.67 (5.69)	<0.001	73.96 (5.32)	80.01 (5.68)	<0.001
BMI, mean (SD)	29.20 (4.56)	28.66 (4.31)	31.05 (4.89)	<0.001	29.50 (4.57)	27.38 (4.03)	<0.001
Charlson Index score, mean (SD)	1.20 (1.66)	1.10 (1.56)	1.55 (1.93)	<0.001	1.10 (1.56)	1.55 (1.93)	0.040
PASE score, mean (SD)	81.93 (44.17)	86.87 (44.34)	65.13 (39.26)	<0.001	85.13 (43.96)	60.73 (43.64)	<0.001
MEDAS score, mean (SD)	7.50 (1.62)	7.57 (1.63)	7.24 (1.58)	<0.001	7.56 (1.61)	7.11 (1.67)	0.002
Time spent in complete 3-meters (ds), mean (SD)	43.51 (21.27)	38.39 (16.57)	60.95 (25.79)	<0.001	40.58 (17.80)	63.21 (29.13)	<0.001
IHS, mean (SD)	24.02 (9.21)	26.51 (8.81)	15.55 (4.12)	<0.001	25.27 (9.03)	15.96 (5.47)	<0.001
ALM/BMI, mean (SD)	0.614 (0.142)	0.651 (0.138)	0.489 (0.062)	<0.001	0.623 (0.144)	0.600 (0.117)	<0.001
Educative level							
Non-educated	417 (28.62%)	270 (23.98%)	147 (44.41%)	<0.001	321 (25.58%)	96 (47.52%)	<0.001
Non-finished primary education	443 (30.40%)	339 (30.11%)	104 (31.42%)	<0.001	380 (30.28%)	63 (31.19%)	<0.001
Finished primary education/superior	597 (40.97%)	517 (45.91%)	80 (24.17%)	<0.001	554 (44.14%)	43 (21.29%)	<0.001
Lawton index score, mean (SD)	6.93 (1.71)	7.05 (1.57)	6.50 (1.71)	<0.001	7.13 (1.47)	5.68 (2.41)	<0.001
Katz Index score, mean (SD)	5.79 (0.59)	5.85 (0.49)	5.56 (0.82)	<0.001	5.84 (0.48)	5.44 (0.99)	<0.001

In bold: p-value < 0.05. ALM/BMI: Appendicular Lean Mass divided by Body Mass Index. EWGSOP2: European Working Group on Sarcopenia in Older People. IHS: Isometric Handgrip Strength. sFNIH: PASE; Physical Activity Scale for the Elderly

Table 2 Associations between physical activity and adherence to the mediterranean diet with two definitions of sarcopenia

	Model 1		Model 2		Model 3		Model 4	
sFNIH	OR (95%CI)	p-value	OR (95%CI)	p-value	OR (95%CI)	p-value	OR (95%CI)	p-value
MEDAS score	0.84 (0.77, 0.91)	<0.001	0.85 (0.78, 0.92)	<0.001	0.85 (0.77, 0.92)	<0.001	0.84 (0.77, 0.92)	<0.001
PASE score	0.91 (0.88, 0.94)	<0.001	0.93 (0.89, 0.96)	<0.001	0.94 (0.91, 0.98)	0.004	0.94 (0.90, 0.97)	0.002
EWGSOP2	OR (95%CI)	p-value	OR (95%CI)	p-value	OR (95%CI)	p-value	OR (95%CI)	p-value
MEDAS score	0.83 (0.75, 0.91)	<0.001	0.83 (0.75, 0.92)	<0.001	0.82 (0.74, 0.91)	<0.001	0.82 (0.74, 0.91)	<0.001
PASE score	0.92 (0.89, 0.96)	<0.001	0.93 (0.89, 0.97)	0.001	0.95 (0.91, 1.00)	0.031	0.95 (0.90, 0.99)	0.018

Model 1: adjusted by age and sex. Model 2: Model 1 + Charlson Index score and number of drugs intake. Model 3: Model 2 + Katz Index score and Lawton Index score. Model 4: Model 3 + educational level, and smoking status

Table 3 Associations between physical activity and adherence to the mediterranean diet with two definitions of sarcopenia considering both independent variables

	Model 1		Model 2		Model 3		Model 4	
sFNIH	OR (95%CI)	p-value	OR (95%CI)	p-value	OR (95%CI)	p-value	OR (95%CI)	p-value
MEDAS score	0.84 (0.77, 0.92)	<0.001	0.85 (0.78, 0.92)	<0.001	0.85 (0.78, 0.92)	<0.001	0.84 (0.77, 0.92)	<0.001
PASE score	0.91 (0.88, 0.95)	<0.001	0.93 (0.90, 0.97)	<0.001	0.95 (0.91, 0.99)	0.008	0.93 (0.90, 0.98)	0.002
EWGSOP2	OR (95%CI)	p-value	OR (95%CI)	p-value	OR (95%CI)	p-value	OR (95%CI)	p-value
MEDAS score	0.83 (0.75, 0.91)	<0.001	0.83 (0.75, 0.92)	<0.001	0.82 (0.74, 0.91)	<0.001	0.82 (0.74, 0.91)	<0.001
PASE score	0.93 (0.89, 0.96)	<0.001	0.93 (0.89, 0.97)	0.001	0.91 (0.91, 1.00)	0.059	0.95 (0.90, 0.99)	0.028

Model 1: adjusted by age, sex, MEDAS score and PASE score. MEDAS score was used as an adjustment variable in the models assessing the role of PASE score, while PASE was used as such adjustment variable was in the models assessing the role of adherence to MD. Model 2: Model 1 + Charlson Index score and number of drugs intake. Model 3: Model 2 + Katz Index score and Lawton Index score. Model 4: Model 3 + educational level, and smoking status

Interactions between MD and PA, and associations with sarcopenia

Table 4 shows the results for the interaction between PA and the adherence to the MD, and its association with sarcopenia. No significant interactions were observed. Similar findings were observed when each sarcopenia domain was tested individually (Supplementary Table 4).

Discussion

The main findings of the present study indicate that PA and adherence to the MD were negatively and significantly associated with sarcopenia. Moreover, PA and MD were significantly associated with specific sarcopenia domains. Indeed, PA was negatively associated with dynapenia and loss of muscle mass, while adherence to the MD was inversely

Table 4 Associations between physical activity, adherence to the mediterranean diet and its interaction with two definitions of sarcopenia

	Model 1		Model 2		Model 3		Model 4	
	OR (95%CI)	p-value	OR (95%CI)	p-value	OR (95%CI)	p-value	OR (95%CI)	p-value
sFNIH								
MEDAS score	0.85 (0.78, 0.93)	<0.001	0.86 (0.79, 0.94)	0.001	0.86 (0.78, 0.94)	0.001	0.85 (0.78, 0.94)	0.001
PASE score	0.91 (0.88, 0.95)	<0.001	0.93 (0.89, 0.97)	<0.001	0.95 (0.91, 0.99)	0.012	0.94 (0.90, 0.98)	0.004
MEDAS*PASE	1.01 (0.99, 1.04)	0.281	1.01 (0.99, 1.04)	0.295	1.01 (0.99, 1.04)	0.208	1.02 (0.99, 1.04)	0.177
EWGSOP2								
MEDAS score	0.83 (0.74, 0.92)	<0.001	0.83 (0.74, 0.92)	0.001	0.82 (0.74, 0.92)	<0.001	0.82 (0.74, 0.92)	<0.001
PASE score	0.92 (0.88, 0.96)	<0.001	0.93 (0.89, 0.97)	0.001	0.96 (0.91, 1.00)	0.078	0.95 (0.90, 1.00)	0.036
MEDAS*PASE	1.00 (0.97, 1.02)	0.942	1.00 (0.97, 1.02)	0.923	1.00 (0.98, 1.03)	0.905	1.00 (0.98, 1.03)	0.868

Model 1: adjusted by age, sex, MEDAS score, PASE score and the interaction between them. Model 2: Model 1 + Charlson Index score and number of drugs intake. Model 3: Model 2 + Katz Index score and Lawton Index score. Model 4: Model 3 + educational level, and smoking status

associated with dynapenia and mobility impairments. Nevertheless, these findings were only observed when PA and MD were examined individually, given that no significant interactions were observed between these variables.

Although a theoretical background allows the assumptions that the adoption of healthy lifestyle habits might contribute to counteracting the genesis and progression of sarcopenia, empiric data are still lacking to support these expectations. Notably, investigations examining the association between adherence to the MD and sarcopenia and sarcopenia-related domains have shown controversial results. In one of the few investigations that examined Mediterranean populations, Cacciatore et al. [22] noted that Italian older adults with high adherence to the MD were less likely to present probable sarcopenia. Our findings are also in line with the observations of Hashemi et al. [40] who found significant associations between adherence to MD and the prevalence of sarcopenia in Iranian middle-aged and older adults. Authors also reported that individuals with the highest adherence to the MD had less mobility limitations. On the other hand, Chan et al. [41] reported no significant associations between adherence to the MD and the prevalence of sarcopenia in high-functioning Chinese older adults. These findings were further expanded by Stanton et al. [42], who observed no associations between MD and sarcopenic domains in Australian older adults with no sarcopenia. Results of pooled analysis are also conflicting, with significant associations found between MD and walking speed [24, 28], whereas associations between MD and sarcopenia were not significant [28].

Differences between these studies might be explained by sample characteristics (middle-aged vs. older adults, physical status), sarcopenia operationalization methods, MD adherence score, and geographical location. For instance, there are currently at least 28 different instruments to assess adherence to the MD [43]. These instruments differ regarding their conceptual background (e.g., MD pyramid, diet quality index), place in which it was validated (Mediterranean versus non-Mediterranean countries), and psychometric properties. In the present study, adherence to the MD

was operationalized using the MEDAS method, which has been cross-culturally adapted, tested against negative outcomes, and validated in different populations [43]. However, there is insufficient information about the properties of many of the MD adherence scores used in other investigations [43]. Then, comparisons among instruments are difficult to perform.

Regarding the geographical location, most of the aforementioned investigations were conducted in non-Mediterranean countries (i.e., Iran, China, and Australia). There are considerable attempts to adapt the MD to non-Mediterranean countries [44]. However, adapted versions are frequently based on erroneous interpretations regarding many characteristics of the MD, such as the type of diet (e.g., vegetarian), food groups (e.g., Mediterranean versus general), alcohol intake, which is expected to be based on red wine during meals, olive oil, the main source of fat, and cooking methods [44, 45]. This scenario led some authors to propose that many investigations have not specifically examined MD [45].

Findings of the present study indicate that older adults with higher PA levels were less likely to be sarcopenic, have dynapenia, and low muscle mass. These findings are in line with several other investigations [17] and support current recommendations that PA might be an important complementary instrument to counteract the genesis and development of sarcopenia [46]. Indeed, the practice of PA and regular exercise emerge as adjustable factors influencing functional outcomes in older adults, reducing age-related oxidative stress and pro-inflammatory markers, stimulating muscle protein synthesis and mitochondrial biogenesis pathways, consequently promoting muscle anabolism and potentially contribute to the maintenance of sarcopenia related parameters [47, 48]. Taking this into account, in our population, the observed association between adherence to the Mediterranean diet and physical activity with a decreased risk of sarcopenia is likely more related to antioxidant and anti-inflammatory mechanisms [47, 49–51] than to factors such as loss of appetite, dysphagia, or other nutrition-related conditions.

An interesting result of the present study is that PA and MD were significantly associated with specific sarcopenia domains. Notably, no significant associations were found between PA and mobility limitations, and between MD and low muscle mass. These observations are likely explained by the fact that, although participants were identified as physically active, it is possible that most of these activities were performed at low intensities. Indeed, most of the day-to-day activities mentioned in the PASE questionnaire are commonly performed at low intensities, or, at least, do not require longer periods of strength production, such as walking outside, light domestic work, and repairs in the house, which might not be sufficient to promote neuromuscular gains [52]. These premises are supported by observational data and a recent pooled, in which moderate-to-vigorous PA, but not light PA, was associated with physical performance [53].

The lack of associations between MD and muscle probably occurred due to the low intake of high-quality protein characteristic of this type of diet pattern. As a matter of fact, most protein present in the MD are from vegetal, instead of animal sources. The main difference between these protein sources regards the content and quality of amino acids (AA), given that animal protein is expected to provide higher contents of branched-chain amino acids (BCAA), and mainly leucine, which are acknowledged as major determinants of muscle protein synthesis [54].

A last important observation of the present study is the lack of interaction between MD and PA. For the best of our knowledge, this is the first investigation that examined this scenario in older adults. Results are surprising, given that people with high PA levels are expected to have better nutritional habits [29]. Moreover, some authors have discussed that the favorable health profiles observed in people with high adherence to the MD might reflect a mediterranean way of living, which includes, among other, regular practice of PA, instead of solely nutritional patterns. In addition, although our models were adjusted for comorbidity using the Charlson Comorbidity Index, it is possible that healthier lifestyle behaviors, such as high levels of physical activity and adherence to the Mediterranean diet, may have attenuated the negative impact of chronic conditions on muscle quality and function, independently of their statistical contribution. This potential moderating effect of healthy lifestyles underscores the relevance of promoting healthy behaviors, particularly among those individuals affected by chronic conditions.

One possible rationale for these results is the relative homogeneity in adherence to the MD observed among participants in this study. Notably, interaction analysis combines both dependent variables; therefore, substantial uniformity in one variable could lead to minimal or negligible effects on

the other. Results might also be a product of limitations of the assessment tools. For instance, adherence to the MD was estimated according to the MEDAS. This scenario limits the conduction of deeper analysis adjusting the data according to important nutritional aspects, such as caloric and protein intake, that are quantified using dietary assessment tools.

Clinical applications.

The findings of this study highlight significant clinical implications for preventing and managing sarcopenia. We demonstrate that an increase of 10.5 points in the PASE score, equivalent to walking half an hour a day, decreases the risk of sarcopenia by 5–6%. This recommendation aligns with the general physical activity guidelines for older adults, which suggest at least 150 min of moderate-to-vigorous physical activity per week [55]. Clinicians can incorporate tailored physical activity recommendations, focusing on strength training and aerobic exercises, alongside dietary counseling that promotes Mediterranean diet principles—rich in fruits, vegetables, whole grains, healthy fats, and lean proteins. Furthermore, although we did not find an interaction between both variables, it is important for clinicians to reinforce both adherence to daily physical activity and adherence to the Mediterranean diet, as each seems to be associated with different aspects of sarcopenia. On the other hand, this manuscript opens the possibility that future studies may explore specific cut-off points of physical activity and adherence to the Mediterranean diet specific to prevent sarcopenia in different populations.

The present study involves other limitations that should be mentioned to contribute to a better interpretation of our data. First, PASE is a self-report scale and the possibility that different results might be acquired using objective PA assessment tools cannot be ruled out. Second, both PASE and MEDAS possess subdomains that might be analyzed individually. Third, we used a version of the MEDAS scale, which only involves 14 items, a fact that may underestimate the effect that some specific items may have on these associations. Future studies including the expanded version of this questionnaire (MEDAS Plus) or food frequency questionnaires (i.e., Food Frequency Questionnaire) could complement our findings. Fourth, our sample was composed of community-dwelling older adults and extrapolation to people in other conditions (e.g., hospitalized) should be carefully made. Finally, the cross-sectional design of this manuscript does not allow any inference on cause-effect relationships or on the impact of PA and adherence to the MD on the time course of sarcopenia and its different domains.

Conclusions

Physical Activity levels and adherence to the Mediterranean diet are independently associated with sarcopenia. Moreover, specific associations were observed between sarcopenia domains and these healthy style habits. Nevertheless, no significant interaction between them was observed.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s40520-025-03064-x>.

Acknowledgements We would like to thank the participants, cohort members, and research team members.

Author contributions AAB, HJCJ and LRM contributed to the study conception and design. Analysis was performed by JAC. The first draft of the manuscript was written by AAB, HJCJ, LRM and all authors commented on previous versions of the manuscript. Funding acquisition was provided by FIGG and LRM. All authors read and approved the final manuscript.

Funding TSHA research was funded by grants from the Spanish Ministry of Economy, Industry and Competitiveness, cofinanced by the European Regional Development Funds (Instituto de Salud Carlos III, PI20/00977) and the Centro de Investigación Biomédica en Red en Fragilidad y Envejecimiento Saludable (CB16/10/00464), Proyecto MITOFUN, Fundación Francisco Soria Melguizo (Sect. 2/2020), Innovative Medicines Initiative Joint Undertaking (grant agreement n°115621). Emanuele Marzetti recognize support from the Italian Ministry of Health (Ricerca Corrente 2023).

Data availability No datasets were generated or analysed during the current study.

Declarations

Competing interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Beard JR, Officer A, De Carvalho IA et al (2016) The world report on ageing and health: A policy framework for healthy ageing. *Lancet* 387:2145–2154
2. The Lancet Healthy Longevity (2024) The decade of healthy ageing: progress and challenges ahead. *Lancet Healthy Longev* 5:e1–e1. [https://doi.org/10.1016/S2666-7568\(23\)00271-4](https://doi.org/10.1016/S2666-7568(23)00271-4)
3. Anker SD, Morley JE, von Haehling S (2016) Welcome to the ICD-10 code for sarcopenia. *J Cachexia Sarcopenia Muscle* 7:512–514. <https://doi.org/10.1002/jcsm.12147>
4. Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing* 48:16–31. <https://doi.org/10.1093/ageing/afy169>
5. Petermann-Rocha F, Balntzi V, Gray SR et al (2021) Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. *J Cachexia Sarcopenia Muscle*. <https://doi.org/10.1002/JCSM.12783>
6. Beaudart C, Zaaria M, Pasleau F et al (2017) Health outcomes of sarcopenia: A systematic review and meta-analysis. *PLoS ONE* 12. <https://doi.org/10.1371/journal.pone.0169548>
7. Yeung SSY, Reijnierse EM, Pham VK et al (2019) Sarcopenia and its association with falls and fractures in older adults: A systematic review and meta-analysis. *J Cachexia Sarcopenia Muscle* 10:485–500. <https://doi.org/10.1002/jcsm.12411>
8. Álvarez-Bustos A, Carnicero-Carreño JA, Davies B et al (2022) Role of sarcopenia in the frailty transitions in older adults: a population-based cohort study. *J Cachexia Sarcopenia Muscle* 13:2352–2360. <https://doi.org/10.1002/jcsm.13055>
9. Álvarez-Bustos A, Carnicero JA, Coelho-Junior HJ et al (2024) Diagnostic and prognostic value of calf circumference for sarcopenia in community-dwelling older adults. *J Nutr Health Aging* 28. <https://doi.org/10.1016/J.JNHA.2024.100290>
10. Davies B, Walter S, Rodríguez-Laso A et al (2022) Differential association of frailty and sarcopenia with mortality and disability: insight supporting clinical subtypes of frailty. *J Am Med Dir Assoc* 23:1712–1716e3. <https://doi.org/10.1016/j.jamda.2022.03.013>
11. Kitamura A, Seino S, Abe T et al (2021) Sarcopenia: prevalence, associated factors, and the risk of mortality and disability in Japanese older adults. *J Cachexia Sarcopenia Muscle* 12:30–38. <https://doi.org/10.1002/JCSM.12651>
12. Xu J, Wan CS, Ktoris K et al (2022) Sarcopenia is associated with mortality in adults: A systematic review and Meta-Analysis. *Gerontology* 68:361–376. <https://doi.org/10.1159/000517099>
13. Jones RL, Paul L, Steultjens MPM, Smith SL (2022) Biomarkers associated with lower limb muscle function in individuals with sarcopenia: a systematic review. *J Cachexia Sarcopenia Muscle*. <https://doi.org/10.1002/JCSM.13064>
14. Rodriguez-Mañas L, Araujo de Carvalho I, Bhasin S et al (2020) ICFSR task force perspective on biomarkers for sarcopenia and frailty. *J Frailty Aging* 9:4–8. <https://doi.org/10.14283/JFA.2019.32>
15. Daly RM, Iuliano S, Fyfe JJ et al (2022) Screening, diagnosis and management of sarcopenia and frailty in hospitalized older adults: recommendations from the Australian and new Zealand society for sarcopenia and frailty research (ANZSSFR) expert working group. *J Nutr Health Aging* 26:637–651. <https://doi.org/10.1007/s12603-022-1801-0>
16. Dent E, Morley JE, Cruz-Jentoft AJ et al (2018) International clinical practice guidelines for sarcopenia (ICFSR): screening, diagnosis and management. *J Nutr Health Aging* 22:1148–1161. <https://doi.org/10.1007/S12603-018-1139-9>
17. Sánchez-Sánchez JL, He L, Morales JS et al (2024) Association of physical behaviours with sarcopenia in older adults: a systematic review and meta-analysis of observational studies. *Lancet Healthy Longev* 5:e108–e119. [https://doi.org/10.1016/S2666-7568\(23\)00241-6/ATTACHMENT/685FB606-21E1-4102-A78D-8367C831A1C8/MMC2.PDF](https://doi.org/10.1016/S2666-7568(23)00241-6/ATTACHMENT/685FB606-21E1-4102-A78D-8367C831A1C8/MMC2.PDF)
18. Gropper SS (2023) The role of nutrition in chronic disease. *Nutrients* 15:664. <https://doi.org/10.3390/NU15030664>

19. Odphp (2015) 2015–2020 Dietary Guidelines for Americans
20. Guasch-Ferré M, Willett WC (2021) The mediterranean diet and health: a comprehensive overview. *J Intern Med* 290:549–566. <https://doi.org/10.1111/JOIM.13333>
21. Willett WC, Sacks F, Trichopoulou A et al (1995) Mediterranean diet pyramid: a cultural model for healthy eating. *Am J Clin Nutr* 61. <https://doi.org/10.1093/AJCN/61.6.1402S>
22. Cacciatore S, Calvani R, Marzetti E et al (2023) Low adherence to mediterranean diet is associated with probable sarcopenia in Community-Dwelling older adults: results from the longevity Check-Up (Lookup) 7+Project. *Nutrients* 15:1026. <https://doi.org/10.3390/NU15041026/S1>
23. Barrea L, Muscogiuri G, Di Somma C et al (2019) Association between mediterranean diet and hand grip strength in older adult women. *Clin Nutr* 38:721–729. <https://doi.org/10.1016/J.CLNU.2018.03.012>
24. Coelho-Júnior HJ, Trichopoulou A, Panza F (2021) Cross-sectional and longitudinal associations between adherence to mediterranean diet with physical performance and cognitive function in older adults: A systematic review and meta-analysis. *Ageing Res Rev* 70:101395. <https://doi.org/10.1016/J.ARR.2021.101395>
25. Granic A, Sayer AA, Robinson SM (2019) Dietary Patterns, Skeletal Muscle Health, and Sarcopenia in Older Adults. *Nutrients* 2019, Vol 11, Page 745 11:745. <https://doi.org/10.3390/NU11040745>
26. Mazza E, Ferro Y, Maurotti S et al (2024) Association of dietary patterns with sarcopenia in adults aged 50 years and older. *Eur J Nutr* 63:1651–1662. <https://doi.org/10.1007/S00394-024-0337-0-6>
27. Marcos-Pardo PJ, González-Gálvez N, López-Vivancos A et al (2020) Sarcopenia, diet, physical activity and obesity in European Middle-Aged and older adults: the lifeage study. *Nutrients* 2021(13):Page8–138. <https://doi.org/10.3390/NU13010008>
28. Van Elswyk ME, Teo L, Lau CS, Shanahan CJ (2022) Dietary patterns and the risk of sarcopenia: A systematic review and Meta-Analysis. *Curr Dev Nutr* 6:nzac001. <https://doi.org/10.1093/CDN/NZAC001>
29. Loprinzi PD, Smit E, Mahoney S (2014) Physical activity and dietary behavior in US adults and their combined influence on health. *Mayo Clin Proc* 89:190–198. <https://doi.org/10.1016/j.mayo.2013.09.018>
30. García-García FJ, Gutierrez Avila G, Alfaro-Acha A et al (2011) The prevalence of frailty syndrome in an older population from Spain. The Toledo study for healthy aging. *J Nutr Health Aging* 15:852–856. <https://doi.org/10.1007/s12603-011-0075-8>
31. Studenski SA, Peters KW, Alley DE et al (2014) The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. *J Gerontol A Biol Sci Med Sci* 69:547–558. <https://doi.org/10.1093/GERONA/GLU010>
32. Dam T-T, Peters KW, Fragala M et al (2014) An Evidence-Based comparison of operational criteria for the presence of sarcopenia. *J Gerontol Biol Sci Med Sci* 69:584–590. <https://doi.org/10.1093/gerona/glu013>
33. Davies B, García F, Ara I et al (2018) Relationship between sarcopenia and frailty in the Toledo study of healthy aging: A population based Cross-Sectional study. *J Am Med Dir Assoc* 19:282–286. <https://doi.org/10.1016/j.jamda.2017.09.014>
34. Ottenbacher KJ, Branch LG, Ray L et al (2002) The reliability of upper- and lower-extremity strength testing in a community survey of older adults. *Arch Phys Med Rehabil* 83:1423–1427. <https://doi.org/10.1053/apmr.2002.34619>
35. Estruch R, Martínez-González MA, Corella D et al (2006) Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. *Ann Intern Med* 145:1–11. <https://doi.org/10.7326/0003-4819-145-1-200607040-00004>
36. Washburn RA, Smith KW, Jette AM, Janney CA (1993) The physical activity scale for the elderly (PASE): development and evaluation. *J Clin Epidemiol* 46:153–162. [https://doi.org/10.1016/0895-4356\(93\)90053-4](https://doi.org/10.1016/0895-4356(93)90053-4)
37. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 40:373–383. [https://doi.org/10.1016/0021-9681\(87\)90171-8](https://doi.org/10.1016/0021-9681(87)90171-8)
38. Katz S, Downs T, Cash H (1970) Progress in development of the index of ADL - PubMed. *Gerontologist* 10:20–30. https://doi.org/10.1093/geront/10.1_Part_1.20
39. Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. *Gerontologist* 9:179–186
40. Hashemi R, Motlagh AD, Heshmat R et al (2015) Diet and its relationship to sarcopenia in community dwelling Iranian elderly: a cross-sectional study. *Nutrition* 31:97–104. <https://doi.org/10.1016/J.NUT.2014.05.003>
41. Chan R, Leung J, Woo J (2016) A prospective cohort study to examine the association between dietary patterns and sarcopenia in Chinese Community-Dwelling older people in Hong Kong. *J Am Med Dir Assoc* 17:336–342. <https://doi.org/10.1016/J.JAMD.A.2015.12.004>
42. Stanton A, Buckley J, Villani A (2019) Adherence to a mediterranean diet is not associated with risk of sarcopenic symptomology: A Cross-Sectional analysis of overweight and obese older adults in Australia. *J Frailty Aging* 8:146–149. <https://doi.org/10.14283/JFA.2018.46>
43. Zaragoza-Martí A, Cabañero-Martínez MJ, Hurtado-Sánchez JA et al (2018) Evaluation of mediterranean diet adherence scores: a systematic review. *BMJ Open* 8. <https://doi.org/10.1136/BMJOPEN-2017-019033>
44. Martínez-González MÁ, Hershey MS, Zazpe I, Trichopoulou A (2017) Transferability of the mediterranean diet to Non-Mediterranean countries. what is and what is not the mediterranean diet. *Nutrients* 9. <https://doi.org/10.3390/NU9111226>
45. Bere E, Brug J (2010) Is the term mediterranean diet a misnomer? *Public Health Nutr* 13:2127–2129. <https://doi.org/10.1017/S1368980010000480>
46. Billot M, Calvani R, Urtamo A et al (2020) Preserving mobility in older adults with physical frailty and sarcopenia: opportunities, challenges, and recommendations for physical activity interventions. *Clin Interv Aging* 15:1675–1690. <https://doi.org/10.2147/CIA.S253535>
47. El Assar M, Álvarez-Bustos A, Sosa P et al (2022) Effect of physical activity/exercise on oxidative stress and inflammation in muscle and vascular aging. *Int J Mol Sci* 23:8713. <https://doi.org/10.3390/IJMS23158713>
48. Marzetti E, Lozanoska-Ochser B, Calvani R et al (2024) Restoring mitochondrial function and muscle satellite cell signaling: remedies against Age-Related sarcopenia. <https://doi.org/10.3390/BIOM14040415>. *Biomolecules* 14:
49. El Assar M, Angulo J, Rodríguez-Mañas L (2020) Frailty as a phenotypic manifestation of underlying oxidative stress. *Free Radic Biol Med* 149:72–77. <https://doi.org/10.1016/j.freeradbiomed.2019.08.011>
50. Raffin J, de Souto Barreto P, Le Traon AP et al (2023) Sedentary behavior and the biological hallmarks of aging. *Ageing Res Rev* 83:101807. <https://doi.org/10.1016/J.ARR.2022.101807>
51. Angulo J, El Assar M, Álvarez-Bustos A, Rodríguez-Mañas L (2020) Physical activity and exercise: strategies to manage frailty. *Redox Biol* 35:101513. <https://doi.org/10.1016/j.redox.2020.101513>
52. Wernbom M, Augustsson J, Thomeé R (2007) The influence of frequency, intensity, volume and mode of strength training on whole muscle cross-sectional area in humans. *Sports Med*

- 37:225–264. <https://doi.org/10.2165/00007256-200737030-00004>
53. Sánchez-Sánchez JL, Mañas A, García-García FJ et al (2019) Sedentary behaviour, physical activity, and sarcopenia among older adults in the TSHA: isotemporal substitution model. *J Cachexia Sarcopenia Muscle* 10:188–198. <https://doi.org/10.1002/jcsm.12369>
54. Duan Y, Li F, Li Y et al (2016) The role of leucine and its metabolites in protein and energy metabolism. *Amino Acids* 48:41–51. <https://doi.org/10.1007/S00726-015-2067-1>
55. WHO guidelines on physical activity and sedentary behaviour <https://www.who.int/publications/i/item/9789240015128>. Accessed 20 Dec 2021

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.